Eiger BioPharmaceuticals
Palo Alto
About Eiger BioPharmaceuticals
Eiger BioPharmaceuticals is a privately held biotechnology company that develops a novel antiviral therapy for Hepatitis Delta, a life-threatening, Orphan Disease with high unmet medical need and no approved therapy. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Its strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $156.3M
- Funding stage: IPO
- Last round: Post-IPO Debt (Jun 2022)
- Ticker: nasdaq:EIGR
- Website: eigerbio.com
- Phone: (650)272-6138
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/eiger-biopharmaceuticals-175465 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.